ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04013880|
Recruitment Status : Withdrawn (Loss of funding)
First Posted : July 10, 2019
Last Update Posted : July 7, 2020
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.
Forma Therapeutics, Inc.
Information provided by (Responsible Party):
Paul Ferrell, Vanderbilt-Ingram Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Recruitment Status :||Withdrawn|
|Estimated Primary Completion Date :||March 31, 2021|
|Estimated Study Completion Date :||March 31, 2022|